Professional and Personal Toxic Exposure in Systemic Sclerosis : Type, Intensity and Probability of Exposition

Overview

Systemic Sclerosis (SSc) is an inflammatory chronic disease that can lead to structural damage and handicap. The SSc physiopathology is multifactorial, including genetic and environmental risk factors. The identification of environmental factors implication is crucial to understand the SSc mechanism, and improves the diagnosis and the treatment of the disease.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 27, 2019

Detailed Description

Studies show that the risk associated with high cumulative exposure to silica and organic solvents appears to be strongly increased in SSc. Moreover, exposure to silica is associated with a specific type of SSc phenotype with a worse prognosis. However, the type, intensity and probability of these expositions are unknown. The aim of the study is to precisely determine type, intensity and probability of toxic substances exposition in Systemic Sclerosis patients through an auto-questionnaire and integration of these data in a computer matrix.

Interventions

  • Behavioral: Questionnaire
    • Questionnaire

Arms, Groups and Cohorts

  • Systemic Sclerosis patient
    • patients affected by SSc according to EULAR 2013 criteria

Clinical Trial Outcome Measures

Primary Measures

  • Analyse type, intensity and probability of toxic substances exposition in Systemic Sclerosis patients through an auto-questionnaire and integration of these data in a computer matrix
    • Time Frame: At baseline (day 0)

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged over 18 years old – Speaking and understanding French language – Being informed about the study and having given his consent – Affected by SSc according to EULAR 2013 criteria Exclusion Criteria:

  • Patient under tutorship – Patient who refuse to participate

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marie-Elise TRUCHETET, MD, PhD, Principal Investigator, CHU Bordeaux

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.